中国药师
中國藥師
중국약사
CHINA PHARMACIST
2014年
2期
293-295
,共3页
沈宇舟%潘旭峰%赵珩
瀋宇舟%潘旭峰%趙珩
침우주%반욱봉%조형
非小细胞肺癌%术后化疗%用药分析%药物利用
非小細胞肺癌%術後化療%用藥分析%藥物利用
비소세포폐암%술후화료%용약분석%약물이용
Non-small cell lung cancer%Postoperative chemotherapy%Analysis of drug use%Drug utilization
目的：：了解非小细胞肺癌患者术后辅助化疗的用药情况。方法：采用病例回顾分析方法，对某院2012年接受术后化疗的非小细胞肺癌患者的药物治疗方案、药物利用情况和药物不良反应进行统计分析。结果：156例患者共使用了8种化疗方案，使用例次最多的是NC(长春瑞滨+卡铂)方案，药物费用最高的是PC(培美曲塞+卡铂)方案。化疗辅助用药中药物利用指数排名前列的是质子泵抑制药、重组人促红细胞生成素、香菇多糖。结论：非小细胞肺癌患者术后化疗方案的选择及辅助用药的选用仍需进一步规范，临床外科医师应与药师密切配合，参与治疗过程的监测，促进合理用药。
目的：：瞭解非小細胞肺癌患者術後輔助化療的用藥情況。方法：採用病例迴顧分析方法，對某院2012年接受術後化療的非小細胞肺癌患者的藥物治療方案、藥物利用情況和藥物不良反應進行統計分析。結果：156例患者共使用瞭8種化療方案，使用例次最多的是NC(長春瑞濱+卡鉑)方案，藥物費用最高的是PC(培美麯塞+卡鉑)方案。化療輔助用藥中藥物利用指數排名前列的是質子泵抑製藥、重組人促紅細胞生成素、香菇多糖。結論：非小細胞肺癌患者術後化療方案的選擇及輔助用藥的選用仍需進一步規範，臨床外科醫師應與藥師密切配閤，參與治療過程的鑑測，促進閤理用藥。
목적：：료해비소세포폐암환자술후보조화료적용약정황。방법：채용병례회고분석방법，대모원2012년접수술후화료적비소세포폐암환자적약물치료방안、약물이용정황화약물불량반응진행통계분석。결과：156례환자공사용료8충화료방안，사용례차최다적시NC(장춘서빈+잡박)방안，약물비용최고적시PC(배미곡새+잡박)방안。화료보조용약중약물이용지수배명전렬적시질자빙억제약、중조인촉홍세포생성소、향고다당。결론：비소세포폐암환자술후화료방안적선택급보조용약적선용잉수진일보규범，림상외과의사응여약사밀절배합，삼여치료과정적감측，촉진합리용약。
Objective:To explore the drug application in the postoperative chemotherapy for the patients with non-small cell lung cancer. Methods:The chemotherapy regimens, drug utilization and adverse drug reactions in the non-small cell lung cancer patients received postoperative chemotherapy in 2012 were statistically analyzed in a retrospective study. Results:Totally 8 kinds of chemother-apy regimens were used in 156 cases. The NC( vinorelbine + carboplatin) regimen was used most frequently and the PC( pemetrexed+ carboplatin) regimen was with the highest expense. Proton pump inhibitors, recombinant human erythropoietin and lentinan were the top three in the adjuvant drugs used in the treatment. Conclusion:It is necessary to further standardize the postoperative chemo-therapy for non-small cell lung cancer patients. Thoracic surgeons along with pharmacists should strengthen the drug use monitoring during the whole treatment process to promote the rational drug use.
